File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 ‐year clinical experience in a tertiary referral center

TitleTamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 ‐year clinical experience in a tertiary referral center
Authors
Keywordsovarian cancer
SERMS
tamoxifen
Issue Date2020
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1743-7563
Citation
Asia-Pacific Journal of Clinical Oncology, 2020, Epub 2020-10-20 How to Cite?
AbstractAim: To review the clinical use and the effectiveness of tamoxifen in patients with advanced or recurrent ovarian cancer. Methods: A retrospective review of clinical records was conducted in patients who received tamoxifen for the treatment of ovarian cancer between 2002 and 2016. We reviewed the clinical setting that it was given, duration of use, patients' tolerability, clinical benefit and progression-free survival. We also attempted to identify predictive markers for response. Results: A total of 92 patients received tamoxifen during this 15-year period. The patients received a median of 2.5 lines of chemotherapy before switching to tamoxifen, and they remained on tamoxifen for a median of 5.6 months (range 0–85 months), with 24 patients receiving it for more than 12 months. Seventy-six patients continued on tamoxifen for more than 2 months. In this group, 75 patients had an evaluable response, either by CA 125 or clinically and clinical benefit rate (defined as complete, partial response and static disease) was seen in 42 patients (56%), with majority of patients having static disease. The median progression-free survival was 5.3 months (95% confidence interval, 2.6–8.1). Tamoxifen was well tolerated. Hormone receptor status was not demonstrated to predict response. Conclusion: Patients with advanced ovarian cancer who have failed previous lines of chemotherapy may achieve static disease with tamoxifen with minimal side effects. Tamoxifen may still have a role in the era of molecular target therapy.
DescriptionHybrid open access
Persistent Identifierhttp://hdl.handle.net/10722/294300
ISSN
2020 Impact Factor: 2.601
2020 SCImago Journal Rankings: 0.730
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, KKL-
dc.contributor.authorNgu, SF-
dc.contributor.authorChu, MMY-
dc.contributor.authorTse, KY-
dc.contributor.authorNgan, HYS-
dc.date.accessioned2020-11-23T08:29:24Z-
dc.date.available2020-11-23T08:29:24Z-
dc.date.issued2020-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, 2020, Epub 2020-10-20-
dc.identifier.issn1743-7555-
dc.identifier.urihttp://hdl.handle.net/10722/294300-
dc.descriptionHybrid open access-
dc.description.abstractAim: To review the clinical use and the effectiveness of tamoxifen in patients with advanced or recurrent ovarian cancer. Methods: A retrospective review of clinical records was conducted in patients who received tamoxifen for the treatment of ovarian cancer between 2002 and 2016. We reviewed the clinical setting that it was given, duration of use, patients' tolerability, clinical benefit and progression-free survival. We also attempted to identify predictive markers for response. Results: A total of 92 patients received tamoxifen during this 15-year period. The patients received a median of 2.5 lines of chemotherapy before switching to tamoxifen, and they remained on tamoxifen for a median of 5.6 months (range 0–85 months), with 24 patients receiving it for more than 12 months. Seventy-six patients continued on tamoxifen for more than 2 months. In this group, 75 patients had an evaluable response, either by CA 125 or clinically and clinical benefit rate (defined as complete, partial response and static disease) was seen in 42 patients (56%), with majority of patients having static disease. The median progression-free survival was 5.3 months (95% confidence interval, 2.6–8.1). Tamoxifen was well tolerated. Hormone receptor status was not demonstrated to predict response. Conclusion: Patients with advanced ovarian cancer who have failed previous lines of chemotherapy may achieve static disease with tamoxifen with minimal side effects. Tamoxifen may still have a role in the era of molecular target therapy.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1743-7563-
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectovarian cancer-
dc.subjectSERMS-
dc.subjecttamoxifen-
dc.titleTamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 ‐year clinical experience in a tertiary referral center-
dc.typeArticle-
dc.identifier.emailChan, KKL: kklchan@hkucc.hku.hk-
dc.identifier.emailNgu, SF: ngusiewf@hku.hk-
dc.identifier.emailChu, MMY: chumy@hku.hk-
dc.identifier.emailTse, KY: tseky@hku.hk-
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityChan, KKL=rp00499-
dc.identifier.authorityNgu, SF=rp01367-
dc.identifier.authorityTse, KY=rp02391-
dc.identifier.authorityNgan, HYS=rp00346-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1111/ajco.13478-
dc.identifier.pmid33079469-
dc.identifier.scopuseid_2-s2.0-85092726420-
dc.identifier.hkuros319251-
dc.identifier.volumeEpub 2020-10-20-
dc.identifier.isiWOS:000579538600001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats